To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development.
USA115th CongressHR-6958| House
| Updated: 10/10/2018
Francis Rooney
Republican Representative
Florida
Cosponsors (1)
Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Drug Price Transparency Act This bill requires the Centers for Medicare & Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Health
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceInflation and pricesInternational organizations and cooperationMedicarePrescription drugs
To provide for a study and report on the feasibility of basing reimbursement rates for Medicare part B drugs and covered part D drugs on the average prices for such drugs in the member-states of the Organization for Economic Cooperation and Development.
USA115th CongressHR-6958| House
| Updated: 10/10/2018
Drug Price Transparency Act This bill requires the Centers for Medicare & Medicaid Services to report on the feasibility of basing payment rates for prescription drugs under Medicare and Medicare Advantage on the average price of such drugs in countries that are members of the Organization for Economic Cooperation and Development (an intergovernmental organization focused on global economic development).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Francis Rooney
Republican Representative
Florida
Cosponsors (1)
Ways and Means Committee, Health Subcommittee, Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Congressional oversightGovernment studies and investigationsHealth care costs and insuranceInflation and pricesInternational organizations and cooperationMedicarePrescription drugs